12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Odanacatib: Phase II data

A double-blind Phase II trial in 243 postmenopausal women with osteoporosis who had previously been treated with alendronate for >=3 years showed that once-weekly 50 mg odanacatib met the primary endpoint of increasing BMD at the femoral neck from baseline to 24 months vs. placebo (1.73% vs. a 0.94% reduction). Odanacatib also met the secondary endpoints of increasing BMD at the hip trochanter (1.83% vs. a 1.35% reduction), total hip...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >